Canada expands transparency initiative to biosimilars, devices with novel technologies
This article was originally published in Clinica
Executive Summary
Health Canada is expanding the scope of an ongoing transparency initiative under which it issues public reports explaining the basis of its decision to approve certain drugs and medical devices.